Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases

American Journal of Clinical Pathology

Volumn 113, Issue 5, 2000, Pages 675-682

  Gancberg, D ^a   Lespagnard, L ^a   Rouas, G ^a   Paesmans, M ^a   Piccart, M ^a   Di Leo, A ^a   Nogaret, J M ^a   Hertens, D ^a   Verhest, A ^a   Larsimont, D ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast; FISH; Fluorescence in situ hybridization; Gene amplification; HER 2; Immunohistochemistry

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB11; MONOCLONAL ANTIBODY TAB250; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

EID: 17944379992     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/0F58-0GRX-FK4R-A6VA     Document Type: Article

References (37)

1. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
2. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30 year follow-up
3. Prognostic importance of c-erbB-2 expression in breast cancer
4. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
5. The product of the human c-erbB-2 gene: A 185-kDa glycoprotein with tyrosine kinase activity
6. Detection and quantitation of HER-2/neu gene amplification in human breast archival material using fluorescence in situ hybridization
7. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
8. Sensitivity of HER2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
9. c-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
10. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
11. Prognostic importance of c-erbB-2 expression in breast cancer
12. HER-2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
13. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
14. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
15. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
16. Pathological prognostic factors in breast cancer, I: The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
17. Grading of invasive carcinoma of the breast
18. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
19. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
20. The subcellular localization of the neu protein in human normal and neoplastic cells
21. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
22. Molecular cytogenetics of primary breast cancer by CGH
23. Optimization of immunohistochemical detection of erbB2 in human breast cancer: Impact of fixation
24. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the US FDA-approved scoring system
25. Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
26. Tissue expression and serum levels of HER-2/neu in patients with breast cancer
27. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
28. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer
29. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
30. The neu oncogene protein is a predictive factor for hematogenous metastases in breast-cancer patients
31. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
32. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model
33. The p185 erbB-2 protein is localized on cell organelles involved in cell motility
34. The neu oncogene: More than a prognostic indicator?
35. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment
36. Quantification of c-erb-B2 gene amplification in breast cancer cells using fluorescence in situ hybridization and digital image analysis